EpiVax works towards a new vaccine against the novel coronavirus. Credit: CDC on Unsplash.

Dutch research and development vaccine institute Intravacc has partnered with US-based biotechnology firm EpiVax to advance a Covid-19 vaccine candidate.

The vaccine is based on Intravacc’s Outer Membrane Vesicles (OMV) platform.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the collaboration agreement, Intravacc’s immunogenic OMV delivery platform will unite with EpiVax’s synthetically generated Covid-19 epitopes designed and optimised using immunoinformatics tools.

The aim is to produce a safe and effective T-cell response against SARS-CoV-2 and other related coronaviruses.

EpiVax CEO and CSO Annie De Groot said: “We are thrilled to enter into a partnership with Intravacc using their very novel ‘click-on’ OMV technology and the highly immunogenic and safe SARS-CoV-2 multi-epitope-bearing peptides designed using the iVAX toolkit at EpiVax.

“We believe that the combination of technologies  and the strength of our longstanding collaboration with Intravacc will lead to the development of an effective and safe vaccine that could rapidly benefit hundreds of millions of people around the globe.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Intravacc and EpiVax plan to begin preclinical studies immediately to select the best peptide candidates for the vaccine.

The OMV-peptide vaccine will be manufactured at Intravacc’s pilot-scale facility for clinical trials set to launch in the fourth quarter of this year.

Intravacc CEO Dr Jan Groen said: “The vaccine is expected to lower the risk that individuals infected with SARS-CoV-2 will require hospitalisation and / or intensive care.

“It also expected to induce long-term memory responses to prevent Covid-19 disease and infection from other beta-corona viruses.”

In March, EpiVax partnered with University of Georgia (UGA) researcher Ted Ross to develop a vaccine against Covid-19 caused by the coronavirus.

Separately, Generex Biotechnology signed a contract with EpiVax to leverage computational tools for identifying epitopes that can produce peptide vaccines against Covid-19.

Later, in April, biotechnology firm Immunomic Therapeutics collaborated with EpiVax and PharmaJet to develop a Covid-19 vaccine candidate.